Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
Pharmacotherapeutic group: Nicotinic acid and derivatives
ATC code: C10AD06
Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.
Acipimox also has a favourable effect on high density lipoproteins (HDL or alpha) which increase during treatment.
Acipimox is rapidly and completely absorbed orally, reaching peak plasma levels within two hours. The half-life is about two hours. It does not bind to plasma proteins; it is not significantly metabolised and is eliminated almost completely intact by the urinary route.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeat-dose toxicity, carcinogenicity and mutagenicity.
There is no evidence from the animal studies that acipimox is teratogenic. However, a higher incidence of immature and underweight foetuses was seen in pregnant animals given higher doses of acipimox. This effect may be due to maternal toxicity.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
